Employees: 2,735
Size HPGC Renmintongtai Pharmaceutical (600829.SS) is a China Health Care company (Pharmaceuticals: Major) with a market value of $701M, the 2897th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥8.72 on 18 Nov 2026.
Performance Over six months the shares fell 6.1%, against -15.3% for the median peer and -20.0% for the China market (cap-weighted) — 9th highest of 21 in its peer set.
Growth Revenue grew 4.3% over the last twelve months (peer median +3.5%); the operating margin is 2.5% (peer median 11.0%).
Valuation It trades at 0.6× enterprise value to sales against a peer median of 1.8× (3rd cheapest of 18).
Price implies For today's price to make sense, revenue must grow about 4% a year for seven years (Req g). Recent delivered growth is +5%, so the hurdle is -1 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 0.2 points above its cost of capital (5.0% WACC).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥10.6B | CN¥10.3B | CN¥10.0B | CN¥10.4B | CN¥9.61B |
| Revenue growth | — | +3% | -3% | +8% | — |
| Gross profit | CN¥879M | CN¥766M | CN¥779M | CN¥909M | CN¥829M |
| EBITDA | n/a | CN¥286M | CN¥363M | CN¥474M | CN¥450M |
| Net income | CN¥159M | CN¥134M | CN¥213M | CN¥292M | CN¥264M |
| Free cash flow | CN¥155M | CN¥283M | CN¥107M | CN¥310M | CN¥301M |
| Capital expenditure | CN¥28.3M | CN¥17.2M | CN¥8.04M | CN¥23.5M | CN¥6.42M |
| Total debt | CN¥1.91B | CN¥2.10B | CN¥2.33B | CN¥2.33B | CN¥2.23B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 600829.SS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -2.4% | -7.0% | 8th highest of 21 |
| 6-month return | -6.1% | -15.3% | 9th highest of 21 |
| Distance from 52-week high | -51.9% | -34.0% | 6th lowest of 21 |
| Revenue growth (TTM) | +4.3% | +3.5% | 9th highest of 18 |
| Operating margin | 2.5% | 11.0% | 5th lowest of 18 |
| EV / Sales | 0.6× | 1.8× | 3rd cheapest of 18 |
| Growth the price implies (Req g, 7 yrs) | 4.0% | -2.0% | 4th most demanding of 10 |
| Growth delivered (Del g) | +5.3% | +1.9% | 5th highest of 10 |
| Hurdle (Req g minus delivered) | -1.4 pp | -5.4 pp | 4th most demanding of 10 |
| ROIC minus cost of capital | +0.2 pp | +1.5 pp | 7th lowest of 15 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| HPGC Renmintongtai Pharmaceutical 600829.SS | China | $701M | -6% | +4% | 2% | 0.6× | 4.0% | +5.3% |
| Nuvectis Pharma NVCT | United States | $698M | +91% | n/a | n/a | n/a | n/a | n/a |
| Mochida Pharmaceutical 4534.T | Japan | $714M | -3% | +16% | 10% | 0.8× | n/a | n/a |
| Earth 4985.T | Japan | $687M | +7% | +4% | 4% | 0.5× | -1.6% | -1.8% |
| Shandong Wit Dyne Health 000915.SZ | China | $687M | -31% | -36% | 36% | 2.5× | n/a | n/a |
| China Traditional Chinese Medicine 0570.HK | Hong Kong | $716M | -31% | -16% | 0% | 0.3× | n/a | n/a |
| Hunan Fangsheng Pharmaceutical 603998.SS | China | $719M | -1% | +12% | 20% | 2.6× | -4.8% | +6.4% |
| Sagimet Biosciences SGMT | United States | $722M | +52% | n/a | n/a | n/a | n/a | n/a |
| Hunan Warrant Pharmaceutical 688799.SS | China | $725M | -34% | -3% | 9% | 3.9× | n/a | n/a |
| Yabao Pharmaceutical 600351.SS | China | $678M | 0% | -3% | 16% | 1.6× | -8.3% | -2.8% |
| Shanghai Jiaoda Onlly 600530.SS | China | $726M | -25% | -2% | -2% | 16.1× | 42.7% | -0.9% |
| Jiangsu Jibeier Pharmaceutical 688566.SS | China | $727M | -9% | +8% | 26% | 3.8× | 5.9% | +11.3% |
| Youcare Pharmaceutical 688658.SS | China | $674M | -49% | -7% | -13% | 1.7× | n/a | n/a |
| Philogen PHIL.MI | Italy | $672M | -11% | +295% | 79% | 0.9× | n/a | n/a |
| Jiangsu Aidea Pharmaceutical 688488.SS | China | $672M | -35% | +7% | 8% | 6.7× | 31.9% | +19.8% |
| Annexon ANNX | United States | $671M | -30% | n/a | n/a | n/a | n/a | n/a |
| Luye Pharma 2186.HK | Hong Kong | $736M | -32% | +3% | 18% | 1.1× | -11.8% | +1.9% |
| Hunan Jiudian Pharmaceutical 300705.SZ | China | $738M | -20% | -5% | 13% | 1.8× | -2.0% | +26.1% |
| Sun Pharma Advanced Research SPARC.NS | India | $660M | +6% | +3,141% | 84% | 2.5× | n/a | n/a |
| Zhuzhou Qianjin Pharmaceutical 600479.SS | China | $746M | -3% | +4% | 11% | 1.4× | -2.1% | 0.0% |
| CARsgen Therapeutics 2171.HK | Hong Kong | $751M | -45% | +68% | -170% | 28.6× | n/a | n/a |